CSIMarket Company Name, Ticker, Customers, else..
 
Bluebird Bio Inc   (BLUE)
Other Ticker:  
 
 
Price: $0.9530 $-0.01 -1.069%
Day's High: $1.01 Week Perf: -13.36 %
Day's Low: $ 0.92 30 Day Perf: -32.89 %
Volume (M): 6,537 52 Wk High: $ 5.53
Volume (M$): $ 6,229 52 Wk Avg: $2.79
Open: $0.97 52 Wk Low: $0.88



 Market Capitalization (Millions $) 104
 Shares Outstanding (Millions) 109
 Employees -
 Revenues (TTM) (Millions $) 22
 Net Income (TTM) (Millions $) -91
 Cash Flow (TTM) (Millions $) 12
 Capital Exp. (TTM) (Millions $) 17

Bluebird Bio Inc
Bluebird Bio Inc. is a biotechnology company that develops gene therapies for severe genetic diseases and cancer. The company is known for its focus on using gene therapy to treat inherited blood disorders, such as beta-thalassemia and sickle cell disease. Bluebird Bio also develops CAR-T cell therapies for various types of cancer. The company's gene therapies involve modifying a patient's own cells to correct or replace the faulty gene responsible for the disease. Bluebird Bio aims to provide long-lasting and potentially curative treatment options for patients suffering from these devastating conditions.


   Company Address: 455 Grand Union Boulevard Somerville 2145 MA
   Company Phone Number: 499-9300   Stock Exchange / Ticker: NASDAQ BLUE
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Bluebird Bio Secures Debt Financing to Support Commercial Launches of Innovative Gene Therapies

Published Mon, Mar 18 2024 12:00 PM UTC

Bluebird Bio Secures Debt Financing to Support Commercial Launches of Gene TherapiesBluebird Bio, a leading biotechnology company, has announced that it has secured a $175 million five-year term loan facility with Hercules Capital. This debt financing will strengthen the company's balance sheet as it focuses on the commercial launches of its three FDA-approved gene therapies...
Product Service News

Bluebird Bio's Outcomes-Based Agreement with Medicaid Marks a Major Breakthrough in Sickle Cell Disease Treatment

Published Mon, Mar 11 2024 12:00 PM UTC

Bluebird Bio Revolutionizes Treatment for Sickle Cell Disease with Outcomes-Based Agreement with MedicaidIn a groundbreaking move, bluebird bio, a biotechnology company based in Somerville, Massachusetts, has announced its first outcomes-based agreement with Medicaid for their revolutionary gene therapy called LYFGENIA (lovotibeglogene autotemcel), also known as lovo-cel. Th...
Product Service News

Long-Term Data Supports beti-cel as a Potential Cure for -Thalassemia Patients Requiring Regular Transfusions

Published Sun, Dec 10 2023 5:02 PM UTC


In a groundbreaking announcement, bluebird bio inc. presented updated data from its gene therapy program at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition. The data showcased the promising potential of beti-cel as a curative gene therapy for patients with transfusion-dependent (TDT) beta-thalassemia, demonstrating durable transfusion independe...
Product Service News

Unlocking a Cure: Bluebird Bio's Gene Therapy for Sickle Cell Disease Shows Promise and Unprecedented Revenue Growth

Published Sat, Dec 9 2023 4:31 PM UTC



In a recent announcement, Bluebird Bio Inc., a biotechnology company based in Massachusetts, revealed promising data from their gene therapy program for the treatment of sickle cell disease. The results, presented at the 65th American Society of Hematology conference, showcased the long-term efficacy, safety, and quality of life improvements observed in patients wh...
Product Service News

Bluebird Bio Unveils Launch Plans for Groundbreaking LYFGENIA Gene Therapy for Sickle Cell Disease

Published Fri, Dec 8 2023 6:01 PM UTC


The U.S-based biotech firm Bluebird Bio, Inc. has unveiled plans for the commercial launch of its groundbreaking LYFGENIA gene therapy, set to transform the management of sickle cell disease in a patient group aged 12 years and older who have a history of vaso-occlusive events (VOEs).
This much-anticipated development follows the FDA's go-ahead for LYFGENIA, known c...





 

Bluebird Bio Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com